Clinical Trial Update: A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Natalizumab in Subjects With Rheumatoid Arthritis Who Have Previously Participated in Study ELN100226-RA201 [Phase 2]

View source ↗

Summary

This document provides a Phase II open-label update on the long-term safety, tolerability, and efficacy of intravenous natalizumab in rheumatoid arthritis patie…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Natalizumab (natalizumab)

Snippet

Sponsor: Biogen | Conditions: Rheumatoid Arthritis | Phase 2 | Status: TERMINATED